Clinical trials: mRNA Vaccination
COVID-19 Pandemic
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety…
- Trial name
- NCT05305300
- Testing
- PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A, PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
- Where
- United Arab Emirates
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Vaccination; Infection, COVID-19
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly
Respiratory tract infections, e.g. caused by SARS-CoV-2, disproportionately affect elderly. Vaccination has shown to be the most cost-effective approach to prevent infections.
- Trial name
- HVaNa (NCT05977127)
- Testing
- Comirnaty
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Respiratory Syncytial Virus (RSV), Infectious Disease
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases.
- Trial name
- NCT06564194
- Testing
- JCXH-108
- Where
- 3 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an…
- Trial name
- NCT05650554
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
SARS-CoV-2 Infection
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
This is a clinical study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination in participants aged 18 years and older. In total approximately 275 participants are planned to be enrolled.
- Trial name
- NCT05364242
- Testing
- VLA2001
- Where
- 4 sites in Netherlands, New Zealand
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chlamydia Trachomatis Immunization
Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,560 people, healthy volunteers welcome
- Sponsor
- Sanofi
Myocardial Injury, Vaccine Adverse Reaction
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.
- Conditions
- Myocardial Injury, Vaccine Adverse Reaction, COVID-19
- Trial name
- NCT05308680
- Testing
- BNT162b2
- Where
- Israel
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation…
- Trial name
- NCT06686654
- Testing
- Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent)
- Where
- 24 sites in United States
- Volunteers
- 1,530 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Elderly People Institutionalized in Long-term Care Services
Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions
The main objective of this study is to describe the humoral and cellular response to BNT162b2 vaccination in people over age 75 institutionalized in the long-term care units of the Paris Public Hospitals (APHP)
- Trial name
- COGEVAX-BIO (NCT04961502)
- Testing
- Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gérond'if
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
Mpox (Monkeypox), Smallpox
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
- Conditions
- Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection
- Trial name
- NCT07379580
- Testing
- BNT166a
- Where
- 6 sites in Democratic Republic of the Congo, South Africa
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
COVID-19 Reactogenicity
The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine.
- Trial name
- NCT07051031
- Testing
- Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Marcel Curlin
COVID-19 Pandemic, SARS-CoV2 Infection
Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences
The first COVID-19 case in Turkey was reported on March 11, 2000. National COVID-19 mass vaccination was initiated on Jan 13, 202, with two doses of CoronaVac (R) inactivated vaccine (of Sinovac), 28 days apart.
- Conditions
- COVID-19 Pandemic, SARS-CoV2 Infection, Immunization; Infection, Health
- Trial name
- HU-CoVaCS (NCT05104385)
- Testing
- Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines
- Where
- Turkey (Türkiye)
- Volunteers
- 1,223 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
COVID-19, Infectious Disease
A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects To identify…
- Trial name
- NCT05743335
- Testing
- JCXH-221
- Where
- 4 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Covid19
Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps
This study will evaluate the effectiveness of utilizing Osteopathic Manipulative Treatment (OMT) procedures as an addition to current mRNA COVID-19 vaccines in terms of enhancing the immune response of participants as assessed by…
- Trial name
- NCT04928456
- Testing
- Osteopathic Manipulative Treatment (OMT)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Western University of Health Sciences
Pandemic Influenza Immunization, Healthy Volunteers
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against…
- Trial name
- NCT06907511
- Testing
- Pandemic flu H5 HA mRNA SD2 vaccine
- Where
- 13 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2…
- Trial name
- NCT05433194
- Testing
- ABO1009-DP
- Where
- United Arab Emirates
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
COVID-19
Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)
This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either…
- Trial name
- NCT05387317
- Testing
- Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose
- Where
- 3 sites in Indonesia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Healthy, Immunization; Infection
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
As previously shown, individuals who experienced COVID-19 have developed some protective immunity to reinfection. The magnitude and duration of protection from reinfection conferred by the infection may be weaker after an…
- Trial name
- CoviCompareP (NCT04824638)
- Testing
- 3 doses of BNT162b2 vaccine, 2 dose of BNT162b2 vaccine
- Where
- 11 sites in France
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Rabies
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
The purpose of this trial is to assess the safety and immunogenicity of an investigational RNActive® rabies vaccine (CV7201) in healthy adults.
- Trial name
- NCT02241135
- Testing
- CV7201 mRNA
- Where
- Germany
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- CureVac